The completion is a routine closing event with no new financial surprises. Focus shifts to pipeline execution for zumilokibart (Phase 2 AD data) and APG273 (asthma development). Monitor upcoming clinical readouts and integration updates for potential catalysts.
Price Chart
Executive Summary
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart (atopic dermatitis) and APG273 (asthma). AbbVie reaffirmed its FY2026 adjusted EPS guidance of $13.87-$14.07 and Q3 guidance of $3.84-$3.88, with the deal expected to dilute EPS by $0.14 in 2026 and $0.46 in 2027 before becoming accretive in 2032.
Key Facts
- Acquisition of Apogee Therapeutics completed for $135.11 per share in cash, total equity value ~$10.9 billion
- Apogee's lead asset zumilokibart (IL-13 mAb) is in Phase 2 for atopic dermatitis with potential best-in-category profile
- Pipeline includes APG273 (IL-13 + TSLP combination) in development for asthma
- AbbVie reaffirms FY2026 adjusted diluted EPS guidance range $13.87-$14.07
- AbbVie reaffirms Q3 2026 adjusted diluted EPS guidance range $3.84-$3.88
- Deal expected to dilute adjusted EPS by $0.14 in 2026 (partial year) and ~$0.46 in 2027, with accretion beginning in 2032
Financial Impact
Total equity value ~$10.9 billion; EPS dilution of $0.14 in 2026 and ~$0.46 in 2027; accretion from 2032
Risk Factors
- Integration of Apogee's operations and pipeline may be more difficult or costly than anticipated
- Clinical trial failure or regulatory setbacks for zumilokibart or APG273
- Competition from existing IL-13/TSLP-targeting therapies (e.g., dupilumab, tezepelumab)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-104940 |
| Document: tm2624674d1_ex99-1.htm | 0001104659-26-104940 |
| Document: 0001104659-26-104940-index-headers.html | 0001104659-26-104940 |
| Document: 0001104659-26-104940-index.html | 0001104659-26-104940 |
| Document: 0001104659-26-104940.txt | 0001104659-26-104940 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $259.93 (−0.70%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $259.93 (−0.11%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $259.93 (+6.59%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.93 (+6.05%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.93 (+6.05%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $259.93 (+3.58%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $259.93 (+1.18%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $259.93 (+13.01%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $259.93 (+24.12%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $259.93 (+27.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access